Cargando…
Systems biology of cisplatin resistance: past, present and future
The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047912/ https://www.ncbi.nlm.nih.gov/pubmed/24874729 http://dx.doi.org/10.1038/cddis.2013.428 |
_version_ | 1782480461048578048 |
---|---|
author | Galluzzi, L Vitale, I Michels, J Brenner, C Szabadkai, G Harel-Bellan, A Castedo, M Kroemer, G |
author_facet | Galluzzi, L Vitale, I Michels, J Brenner, C Szabadkai, G Harel-Bellan, A Castedo, M Kroemer, G |
author_sort | Galluzzi, L |
collection | PubMed |
description | The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fully ascribed to its ability to generate unrepairable DNA lesions, hence inducing either a permanent proliferative arrest known as cellular senescence or the mitochondrial pathway of apoptosis. Accumulating evidence now suggests that the cytostatic and cytotoxic activity of cisplatin involves both a nuclear and a cytoplasmic component. Despite the unresolved issues regarding its mechanism of action, the administration of cisplatin is generally associated with high rates of clinical responses. However, in the vast majority of cases, malignant cells exposed to cisplatin activate a multipronged adaptive response that renders them less susceptible to the antiproliferative and cytotoxic effects of the drug, and eventually resume proliferation. Thus, a large fraction of cisplatin-treated patients is destined to experience therapeutic failure and tumor recurrence. Throughout the last four decades great efforts have been devoted to the characterization of the molecular mechanisms whereby neoplastic cells progressively lose their sensitivity to cisplatin. The advent of high-content and high-throughput screening technologies has accelerated the discovery of cell-intrinsic and cell-extrinsic pathways that may be targeted to prevent or reverse cisplatin resistance in cancer patients. Still, the multifactorial and redundant nature of this phenomenon poses a significant barrier against the identification of effective chemosensitization strategies. Here, we discuss recent systems biology studies aimed at deconvoluting the complex circuitries that underpin cisplatin resistance, and how their findings might drive the development of rational approaches to tackle this clinically relevant problem. |
format | Online Article Text |
id | pubmed-4047912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40479122014-06-12 Systems biology of cisplatin resistance: past, present and future Galluzzi, L Vitale, I Michels, J Brenner, C Szabadkai, G Harel-Bellan, A Castedo, M Kroemer, G Cell Death Dis Review The platinum derivative cis-diamminedichloroplatinum(II), best known as cisplatin, is currently employed for the clinical management of patients affected by testicular, ovarian, head and neck, colorectal, bladder and lung cancers. For a long time, the antineoplastic effects of cisplatin have been fully ascribed to its ability to generate unrepairable DNA lesions, hence inducing either a permanent proliferative arrest known as cellular senescence or the mitochondrial pathway of apoptosis. Accumulating evidence now suggests that the cytostatic and cytotoxic activity of cisplatin involves both a nuclear and a cytoplasmic component. Despite the unresolved issues regarding its mechanism of action, the administration of cisplatin is generally associated with high rates of clinical responses. However, in the vast majority of cases, malignant cells exposed to cisplatin activate a multipronged adaptive response that renders them less susceptible to the antiproliferative and cytotoxic effects of the drug, and eventually resume proliferation. Thus, a large fraction of cisplatin-treated patients is destined to experience therapeutic failure and tumor recurrence. Throughout the last four decades great efforts have been devoted to the characterization of the molecular mechanisms whereby neoplastic cells progressively lose their sensitivity to cisplatin. The advent of high-content and high-throughput screening technologies has accelerated the discovery of cell-intrinsic and cell-extrinsic pathways that may be targeted to prevent or reverse cisplatin resistance in cancer patients. Still, the multifactorial and redundant nature of this phenomenon poses a significant barrier against the identification of effective chemosensitization strategies. Here, we discuss recent systems biology studies aimed at deconvoluting the complex circuitries that underpin cisplatin resistance, and how their findings might drive the development of rational approaches to tackle this clinically relevant problem. Nature Publishing Group 2014-05 2014-05-29 /pmc/articles/PMC4047912/ /pubmed/24874729 http://dx.doi.org/10.1038/cddis.2013.428 Text en Copyright © 2014 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Review Galluzzi, L Vitale, I Michels, J Brenner, C Szabadkai, G Harel-Bellan, A Castedo, M Kroemer, G Systems biology of cisplatin resistance: past, present and future |
title | Systems biology of cisplatin resistance: past, present and future |
title_full | Systems biology of cisplatin resistance: past, present and future |
title_fullStr | Systems biology of cisplatin resistance: past, present and future |
title_full_unstemmed | Systems biology of cisplatin resistance: past, present and future |
title_short | Systems biology of cisplatin resistance: past, present and future |
title_sort | systems biology of cisplatin resistance: past, present and future |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4047912/ https://www.ncbi.nlm.nih.gov/pubmed/24874729 http://dx.doi.org/10.1038/cddis.2013.428 |
work_keys_str_mv | AT galluzzil systemsbiologyofcisplatinresistancepastpresentandfuture AT vitalei systemsbiologyofcisplatinresistancepastpresentandfuture AT michelsj systemsbiologyofcisplatinresistancepastpresentandfuture AT brennerc systemsbiologyofcisplatinresistancepastpresentandfuture AT szabadkaig systemsbiologyofcisplatinresistancepastpresentandfuture AT harelbellana systemsbiologyofcisplatinresistancepastpresentandfuture AT castedom systemsbiologyofcisplatinresistancepastpresentandfuture AT kroemerg systemsbiologyofcisplatinresistancepastpresentandfuture |